Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
Siobhan Calafiore, Senior Journalist at the limbic, shared a post on LinkedIn about a recent article she authored, published in The Limbic:
“This week I reported on the landmark COBRRA trial addressing one of the common clinical dilemmas for haematologists treating community-acquired blood clots, ‘which anticoagulant do I give my patient?’
For years, clinical guidelines have been unable to preference one DOAC over the other due to a complete lack of head-to-head trials.
The latest findings suggest while both DOACs work well to prevent recurrent blood clots, apixaban is safer than rivaroxaban, more than halving the risk of bleeding.
Australia had a big role to play in this practice-changing study and I was lucky enough to chat to Australia’s lead investigator Vivien Chen about the practical difference these findings will make in everyday practice around the world. ”
Title: Landmark VTE trial backs apixaban over rivaroxaban
Authors: Siobhan Calafiore
Read the Full Article on The Limbic
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda
-
Aug 11, 2026, 05:38Rami Unterman: A Simple New Biomarker for Fibrotic ILDs
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria